Collaborative Arrangements (Tables)

9 Months Ended

Sep. 30, 2022

Summary of Total Consolidated Revenue from Strategic Collaborators

The following table summarizes our total consolidated revenue from our current and former strategic collaborators for the periods presented (in thousands):

	THREE MONTHS ENDED SEPTEMBER 30,				NINE MONTHS ENDED SEPTEMBER 30,
Collaboration Revenue by Strategic Collaborator:	2022		2021		2022			2021
Jazz	$	28	$	118	$	26,044		$	11,225
Sarepta		—		1,039		(167	)		4,013
Total collaboration revenue	$	28	$	1,157	$	25,877		$	15,238

Schedule of Changes in Contract Assets and Liabilities

The following tables present changes in the Company’s contract assets and liabilities for the period presented (in thousands):

	NINE MONTHS ENDED SEPTEMBER 30, 2022
	BALANCE BEGINNING OF PERIOD		ADDITIONS		DEDUCTIONS			BALANCE END OF PERIOD
Contract assets:
Account receivable (1)	$	628		—		(628	)	$	—
Contract liabilities:
Deferred revenue	$	43,649		—		(26,044	)	$	17,605

(1)Included in prepaid expenses and other current assets as shown within the condensed consolidated balance sheets.

Schedule of Revenue Recognized

During the three and nine months ended September 30, 2022 and 2021, the Company recognized the following revenue (in thousands):

	THREE MONTHS ENDED SEPTEMBER 30,				NINE MONTHS ENDED SEPTEMBER 30,
	2022		2021		2022		2021
Revenue recognized in the period from:
Amounts included in deferred revenue at the beginning of the period	$	28	$	1,157	$	26,044	$	15,238

Jazz Pharmaceuticals Ireland Limited

Schedule of Research and Development Costs Incurred and Revenue Recognized

The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the Jazz Collaboration Agreement (in thousands):

	THREE MONTHS ENDED SEPTEMBER 30,				NINE MONTHS ENDED SEPTEMBER 30,
	2022		2021		2022		2021
Revenue recognized	$	28	$	118	$	26,044	$	11,225
Costs incurred	$	226	$	606	$	1,178	$	1,947

Sarepta Therapeutics

Schedule of Research and Development Costs Incurred and Revenue Recognized

The following table summarizes research and development costs incurred and revenue recognized in connection with Company's performance under the Sarepta Research Agreement (in thousands):

	THREE MONTHS ENDED SEPTEMBER 30,				NINE MONTHS ENDED SEPTEMBER 30,
	2022		2021		2022			2021
Revenue recognized	$	—	$	1,039	$	(167	)	$	4,013
Costs incurred	$	—	$	1,039	$	—		$	4,013